Please sign in to follow a disease.
Rheumatic disorder
MONDO:0005554Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.
Also known as: rheumatic disease, rheumatologic disorder, collagen disease, collagen vascular disease, connective tissue disease, disease, rheumatic, diseases, rheumatic, enthesopathies
1792 clinical trials for this condition and its sub-types, 90 tagged with Rheumatic disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Rheumatic disorder
-
Rheumatoid arthritis 576 trials · 795 incl. sub-types
7 sub-types
- Psoriatic arthritis 188 trials · 201 incl. sub-types Sub-types →
- Ankylosing spondylitis 109 trials · 113 incl. sub-types Sub-types →
- Rheumatoid arthritis-associated interstitial lung disease 12 trials
- Chronic childhood arthritis 5 trials
- Felty syndrome 0 trials
- Polyarticular juvenile rheumatoid arthritis 0 trials
- Rheumatoid vasculitis 0 trials
-
Lupus erythematosus 39 trials · 548 incl. sub-types
3 sub-types
- Systemic lupus erythematosus 516 trials · 522 incl. sub-types Sub-types →
- Cutaneous lupus erythematosus 38 trials · 46 incl. sub-types Sub-types →
- Drug-induced lupus erythematosus 1 trial
-
Scleroderma 47 trials · 305 incl. sub-types
3 sub-types
- Systemic sclerosis 261 trials · 295 incl. sub-types Sub-types →
- Localized scleroderma 14 trials · 15 incl. sub-types Sub-types →
- Neonatal scleroderma 0 trials
-
Autoinflammatory syndrome 21 trials · 207 incl. sub-types
37 sub-types
- Sarcoidosis 61 trials · 84 incl. sub-types Sub-types →
- Periodic fever syndrome 2 trials · 25 incl. sub-types Sub-types →
- Systemic-onset juvenile idiopathic arthritis 25 trials
- Type 1 interferonopathy 4 trials · 21 incl. sub-types Sub-types →
- Autoinflammatory syndrome of childhood 0 trials · 19 incl. sub-types Sub-types →
- VEXAS syndrome 18 trials
- Adult-onset Still disease 12 trials
- Pyoderma gangrenosum 10 trials Sub-types →
- Idiopathic recurrent pericarditis 8 trials
- PFAPA syndrome 6 trials
- Chronic recurrent multifocal osteomyelitis 3 trials · 4 incl. sub-types Sub-types →
- SAPHO syndrome 3 trials
- Schnitzler syndrome 1 trial
- Cherubism 1 trial Sub-types →
- CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome 0 trials
- F12-associated cold autoinflammatory syndrome 0 trials
- PAPASH syndrome 0 trials
- Pelger-Huet-like anomaly and episodic fever with abdominal pain 0 trials
- SAMD9L-associated autoinflammatory syndrome 0 trials
- Sharpin-related autoinflammatory syndrome 0 trials
- Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation 0 trials
- Autoinflammatory disease, X-linked 0 trials
- Autoinflammatory disease, multisystem, with immune dysregulation, X-linked 0 trials Sub-types →
- Autoinflammatory disease, systemic, with vasculitis 0 trials
- Autoinflammatory syndrome with immunodeficiency 0 trials
- Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis 0 trials
- Autoinflammatory syndrome, familial, Behcet-like 0 trials Sub-types →
- Autoinflammatory syndrome due to TBK1 deficiency 0 trials
- Early-onset pulmonary and cutaneous vasculitis 0 trials
- Granulomatous autoinflammatory syndrome of childhood 0 trials
- Infantile onset panniculitis with uveitis and systemic granulomatosis 0 trials
- Magic syndrome 0 trials
- Neonatal inflammatory skin and bowel disease 0 trials Sub-types →
- Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 0 trials
- Psoriasis 14, pustular 0 trials
- Pyoderma gangrenosum-acne-suppurative hidradenitis syndrome 0 trials
- Pyogenic arthritis-pyoderma gangrenosum-acne syndrome 0 trials
-
Juvenile idiopathic arthritis 107 trials · 115 incl. sub-types
6 sub-types
- Systemic-onset juvenile idiopathic arthritis 25 trials
- Polyarticular juvenile idiopathic arthritis 14 trials · 16 incl. sub-types Sub-types →
- Psoriasis-related juvenile idiopathic arthritis 15 trials
- Enthesitis-related juvenile idiopathic arthritis 7 trials
- Oligoarticular juvenile idiopathic arthritis 5 trials Sub-types →
- Unspecified juvenile idiopathic arthritis 0 trials
-
Dermatomyositis 81 trials · 100 incl. sub-types
11 sub-types
- Juvenile dermatomyositis 41 trials
- Anti-MDA5 dermatomyositis 3 trials
- Clinically amyopathic dermatomyositis 1 trial · 2 incl. sub-types Sub-types →
- Adermatopathic dermatomyositis 0 trials
- Adult dermatomyositis 0 trials
- Anti-Mi2 dermatomyositis 0 trials
- Anti-NXP2 dermatomyositis 0 trials
- Anti-SAE dermatomyositis 0 trials
- Anti-TIF1 dermatomyositis 0 trials
- Classical dermatomyositis 0 trials
- Neonatal dermatomyositis 0 trials
-
Polymyalgia rheumatica 30 trials
-
Rheumatic fever 16 trials
-
Mixed connective tissue disease 15 trials
-
Reactive arthritis 6 trials
-
Gorham-Stout disease 2 trials
-
Sweet syndrome 2 trials
-
Palindromic rheumatism 1 trial
-
2 sub-types
- Inflammatory bowel disease 25 0 trials
- Inflammatory bowel disease 28 0 trials
-
LAMA5-related multisystemic syndrome 0 trials
-
Reye syndrome 0 trials
-
Wissler syndrome 0 trials
-
Acroosteolysis dominant type 0 trials
-
Chondrocalcinosis 2 0 trials
-
Fibroblastic rheumatism 0 trials
-
Idiopathic juvenile osteoporosis 0 trials
-
Intermittent hydrarthrosis 0 trials
-
Progeria-associated arthropathy 0 trials
-
Rheumatic pulmonary valve disease 0 trials
Most studied deeper sub-types
-
Can an oral drug calm inflamed muscles in myositis?
Disease control Stopped earlyResearchers are testing an experimental oral drug called enpatoran in adults with dermatomyositis and polymyositis, two rare muscle-weakening diseases. Participants receive enpatoran or a placebo twice daily for up to 24 weeks while continuing their standard care. The trial measu…
Phase 2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Experimental CAR-T therapy takes aim at Hard-to-Treat scleroderma
Disease control Stopped earlyThis early-phase trial is testing a new treatment called KYV-101 for people with systemic sclerosis, a disease where the immune system attacks the body, causing skin and organ damage. The therapy uses a patient's own modified immune cells to target and destroy certain B cells tha…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat lupus nephritis
Disease control Stopped earlyThis early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 p…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Lupus skin drug trial halted early – only 8 volunteers joined
Disease control Stopped earlyThis study tested an experimental drug called PF-06823859 for adults with lupus that affects the skin. The goal was to see if the drug could reduce skin inflammation and improve symptoms. The trial was stopped early and only enrolled 8 people instead of the planned 48, so results…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new biologic tame lupus flares?
Disease control Stopped earlyThis trial is testing whether an experimental biologic called MK-6194 can reduce disease activity in adults with systemic lupus erythematosus (SLE), an autoimmune condition that causes inflammation and organ damage. Participants receive either MK-6194 or a placebo as an injection…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new hip implant stand the test of time?
Disease control Stopped earlyThis study follows about 300 people who receive a hip replacement using the GTS cementless stem, a type of implant that anchors to bone without cement. The goal is to see how well the implant performs over up to 10 years, measuring pain, function, and joint stability. Participant…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Rheumatoid arthritis combo drug trial stalls after just 2 patients
Disease control Stopped earlyThis early-stage trial tested whether adding an experimental drug called VIB4920 to standard TNF-inhibitor therapy could improve disease control in people with rheumatoid arthritis. Only 2 participants were enrolled before the study was terminated, so no meaningful conclusions ca…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New arthritis drug trial for kids: could filgotinib help?
Disease control Stopped earlyThis study is testing the drug filgotinib in children aged 8 to 17 with juvenile idiopathic arthritis (JIA), a condition causing joint pain and swelling. The goal is to see how the drug moves through the body and if it is safe. Ten children with moderate to severe JIA that is not…
Phase 1 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Ankle implant tracked for Long-Term success in arthritis patients
Disease control Stopped earlyThis study followed 65 adults with ankle arthritis (from wear-and-tear, injury, or conditions like rheumatoid arthritis) who received the Cadence Total Ankle System implant. Researchers tracked how long the implant lasted without needing removal or revision, checking at 2, 5, and…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New RA drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called LY3541860 in 35 adults with moderate-to-severe rheumatoid arthritis who had not improved enough on other treatments. The goal was to see if the drug could reduce joint swelling and pain. However, the trial was terminated early, so the…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control Stopped earlyThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Phase 1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control Stopped earlyThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Shoulder implant under review: will it last 10 years?
Disease control Stopped earlyThis study looked at a shoulder implant used to treat pain and joint problems from conditions like arthritis, fractures, and rotator cuff tears. It involved 67 adults who received the implant and tracked how long it lasted and any side effects over 10 years. The goal was to confi…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill for rheumatoid arthritis shows promise in early trial
Disease control Stopped earlyThis phase 2 study tested an experimental oral drug called BGB-45035 in 49 adults with moderate to severe rheumatoid arthritis who had not responded well to standard treatments. Participants received either the drug or a placebo to see if it could reduce joint pain and swelling. …
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Rheumatoid arthritis drug study halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called GS-0272 in adults with rheumatoid arthritis to see if it is safe and how the body processes it. The trial was stopped early, so results are limited. About 55 people were planned to take part, receiving either the drug or a placebo.
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Discoid lupus drug trial halted midway
Disease control Stopped earlyThis study tested an experimental drug called daxdilimab in 72 adults with moderate-to-severe discoid lupus erythematosus, a skin condition that causes scarring and hair loss. The goal was to see if the drug could reduce disease activity compared to a placebo. However, the trial …
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Experimental drug TPN-101 tested in rare childhood brain disease
Disease control Stopped earlyThis study tested a drug called TPN-101 (censavudine) in people with Aicardi-Goutières syndrome, a rare genetic disorder that causes severe brain inflammation. The trial enrolled only 4 participants and aimed to see if the drug could reduce immune system overactivity and check fo…
Phase 2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Lupus flare prevention drug trial halted early
Disease control Stopped earlyThis study tested a drug called PRV-3279 to see if it could prevent lupus flares in people with active systemic lupus erythematosus (SLE). The trial included 28 adults with moderate to severe lupus who had improved after steroid treatment. The study was terminated early, so resul…
Phase 2 • Sponsor: Provention Bio, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Promising drug for rare skin ulcers shows early potential
Disease control Stopped earlyThis study tested a drug called spesolimab in 5 adults with moderate to severe pyoderma gangrenosum, a rare autoimmune disease that causes painful skin ulcers. The goal was to see if the drug could help heal the ulcers and to understand how the body's immune system responds. The …
Phase 2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
CBD-Hydroxychloroquine combo tested for arthritis pain – but trial ends early
Disease control Stopped earlyThis study tested a combination pill called IHL-675A, which contains cannabidiol (CBD) and hydroxychloroquine, in people with rheumatoid arthritis. The goal was to see if it safely reduces pain and improves daily function. The trial planned to enroll 128 volunteers but was termin…
Phase 2 • Sponsor: Incannex Healthcare Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental drug HZN-825 tested for rare scleroderma lung and skin damage
Disease control Stopped earlyThis trial tested an experimental drug called HZN-825 in about 300 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and can damage the lungs. Participants took either a low dose, a high dose, or a placebo daily for 52 weeks. …
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New shoulder implant tested for severe arthritis – but study halted early
Disease control Stopped earlyThis study looked at the TITAN Reverse Shoulder System, a device used to replace the shoulder joint in people with severe arthritis and a torn rotator cuff. The goal was to see if it relieves pain and improves movement. About 151 people were planned to take part, but the study wa…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Lupus skin drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental oral drug called edecesertib (GS-5718) in 20 people with cutaneous lupus erythematosus, a condition where lupus affects the skin. The goal was to see if the drug could reduce skin disease activity and improve symptoms. However, the trial was term…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental drug vixarelimab tested for two scarring lung diseases
Disease control Stopped earlyThis study tested the drug vixarelimab against a placebo in people with idiopathic pulmonary fibrosis (IPF) or systemic sclerosis-associated interstitial lung disease (SSc-ILD). The goal was to see if it could preserve lung function over 52 weeks. The trial was terminated early, …
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental CAR t therapy targets lupus and related diseases – but trial ends early
Disease control Stopped earlyThis early-phase trial tested a single infusion of IMPT-514, a personalized CAR T cell therapy, in 3 adults with severe lupus, vasculitis, or inflammatory myopathy that did not respond to standard treatments. The goal was to check safety and see if the therapy could reset the imm…
Early phase 1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Early-Stage lung blood pressure drug trial halted
Disease control Stopped earlyThis study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either …
Phase 2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Lupus drug trial halted early: what we know
Disease control Stopped earlyThis study tested a weekly injection called telitacicept against a placebo in 91 people with moderate-to-severe lupus. The goal was to see if the drug could reduce disease activity and allow lower steroid doses. However, the trial was terminated early, so we have less information…
Phase 3 • Sponsor: Vor Biopharma • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental drug HZN-825 tested for rare autoimmune lung complication
Disease control Stopped earlyThis trial tested the drug HZN-825 in 174 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that can scar the lungs. Participants took the drug twice daily for 52 weeks to see if it helped maintain lung function and to check for side effects. The study w…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control Stopped earlyThis study tested a medicine called Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if weekly shots under the skin could improve symptoms better than a placebo. The study was stopped early, but res…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Lupus kidney drug trial halted midway
Disease control Stopped earlyThis study tested a drug called zetomipzomib for people with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if the drug could improve kidney function better than a placebo over 52 weeks. The trial was terminated early, so results are limited. Partic…
Phase 2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug peresolimab tested for rheumatoid arthritis – study ends early
Disease control Stopped earlyThis study tested peresolimab, an experimental drug, in 491 adults with moderately-to-severely active rheumatoid arthritis who had not responded well to other treatments. The goal was to see if peresolimab could reduce joint pain and swelling better than a placebo. However, the s…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Sarcoidosis drug study halted after just 3 patients
Disease control Stopped earlyThis study tested whether the drug maraviroc could reduce inflammation in the lungs of people with active sarcoidosis. Participants took the drug for 6 weeks and had two lung exams (bronchoscopy) to measure immune cells before and after treatment. Only 3 people enrolled, and the …
Sponsor: Kevin F. Gibson • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Smart device helps arthritis patients stay on track
Disease control Stopped earlyThis study looked at whether a smart injection device (Smartclic) helps rheumatoid arthritis patients take their etanercept medication as prescribed. Researchers tracked 60 patients in Colombia for 40 weeks, measuring how often they used the device and how their symptoms changed.…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Promising drug trial for painful skin ulcers halted early
Disease control Stopped earlyThis study tested a drug called vilobelimab for people with pyoderma gangrenosum, a rare condition causing painful skin ulcers. The trial aimed to see if the drug could completely close the ulcers compared to a placebo. It included 54 adults and was stopped early, so the results …
Phase 3 • Sponsor: InflaRx GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New wound therapy for rare skin disease shows early promise
Disease control Stopped earlyThis study tested a treatment for pyoderma gangrenosum, a rare skin condition that causes painful, hard-to-heal ulcers. Researchers used a special wound covering made from donated placenta tissue (EpiFix) followed by skin grafts. The study was stopped early after only 5 people en…
Phase 4 • Sponsor: Louisiana State University Health Sciences Center in New Orleans • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Knee implant study halted early: what we know
Disease control Stopped earlyThis study looked at how well the P.F.C. Sigma knee replacement implant works in people with severe knee arthritis. Researchers planned to follow 723 patients for at least 5 years after surgery, tracking pain, function, and any complications. However, the study was terminated ear…
Phase 4 • Sponsor: DePuy International • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can a smartphone app replace doctor visits for arthritis patients?
Disease control Stopped earlyThis study tested whether using a smartphone app and a hand grip device could help people with rheumatoid arthritis manage their condition with fewer in-person doctor visits. About 94 adults with active rheumatoid arthritis were randomly assigned to use the app or continue standa…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug namilumab tested for lung sarcoidosis – but trial halted early
Disease control Stopped earlyThis study tested namilumab, an experimental drug, in 107 people with chronic pulmonary sarcoidosis, a condition causing lung inflammation. The trial was randomized and placebo-controlled, but it was terminated early. The goal was to see if namilumab could reduce the need for res…
Phase 2 • Sponsor: Kinevant Sciences GmbH • Aim: Disease control
Last updated Jun 26, 2026 15:32 UTC
-
Lupus drug combo tested in tiny trial – but study halted early
Disease control Stopped earlyThis phase 2 trial tested the drugs mycophenolate mofetil (CellCept) alone or with voclosporin in 12 people with lupus. The goal was to see if these treatments work better in certain patient groups. However, the study was terminated early, so the results are very limited.
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 26, 2026 15:22 UTC
-
New PET tracer aims to reveal hidden immune activity in tumors and arteries
Diagnosis Stopped earlyThis Phase II study tested a radioactive tracer called 68GaNOTA-Anti-MMR-VHH2 to see if it can light up certain immune cells (macrophages) on PET scans. The trial included 29 people with head and neck cancer, lymphoma, atherosclerosis, or sarcoidosis. The goal was to see if the t…
Phase 2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New PET tracer aims to light up inflammation in joint and muscle diseases
Diagnosis Stopped earlyThis early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection o…
Phase 1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Diagnosis
Last updated Jun 26, 2026 18:25 UTC
-
Can High-Tech toothbrushes protect gums in scleroderma?
Symptom relief Stopped earlyThis trial tests whether using a sonic toothbrush and a water flosser improves gum health better than a standard manual toothbrush in people with systemic sclerosis, a rare disease that often affects the mouth. About 20 adults with the condition will be randomly assigned to one o…
Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Pain pill showdown: ultracet vs. voltaren for back inflammation
Symptom relief Stopped earlyThis study compared two pain medications—Ultracet (tramadol/acetaminophen) and Voltaren (diclofenac)—in people with ankylosing spondylitis who were already taking disease-modifying anti-rheumatic drugs (DMARDs). The goal was to see which one worked better for pain relief over 8 w…
Phase 4 • Sponsor: Johnson & Johnson Taiwan Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Sarcoidosis drug study halted after only 2 patients enrolled
Symptom relief Stopped earlyThis study tested whether Acthar gel could improve symptoms and lung function in people with sarcoidosis, a disease that causes inflammation in the lungs. Researchers also checked if a blood marker called CXCL9 could predict how well the treatment works. Only 2 people joined befo…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 12:27 UTC
-
New injection targets psoriatic arthritis pain in small trial
Symptom relief Stopped earlyThis early-stage study tested the safety of an experimental drug called Allocetra, injected directly into the joint, for people with psoriatic arthritis. Only 5 participants were enrolled. The main goal was to check for side effects, with some initial data on pain relief. The stu…
Phase 1 • Sponsor: Enlivex Therapeutics Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Laser hope for scars and scleroderma fizzles in tiny trial
Symptom relief Stopped earlyThis study tested whether a special laser could improve scars and skin hardening from scleroderma. Only 6 people took part, and the study was stopped early. Researchers measured scar changes using a standard scale, but the small size and early termination mean we cannot draw firm…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Could a tiny ear device ease arthritis pain in kids?
Symptom relief Stopped earlyThis study tested whether a small device that sends mild electrical pulses to the vagus nerve (through the ear) can reduce pain and inflammation in children with juvenile idiopathic arthritis. The trial planned to enroll children ages 5 to 18, but was terminated early after only …
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
RA patients paired with buddies to boost Well-Being
Symptom relief Stopped earlyThis study tested a program where people with rheumatoid arthritis (RA) were paired with a trained peer supporter for up to 6 months. The goal was to see if sharing experiences and support could improve daily function, medication adherence, and symptoms like pain and fatigue. The…
Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Painkiller showdown: which is safer for the heart?
Knowledge-focused Stopped earlyThis study looked at how two common pain relievers—celecoxib (a Coxib) and naproxen (an NSAID)—affect blood clotting in people with rheumatoid arthritis who also have heart disease or are at high risk for it. All participants took low-dose aspirin daily. The goal was to see if on…
Phase 4 • Sponsor: Platelet and Thrombosis Research, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Scientists hunt for clues to tell infection apart from inflammation in Kids' joints
Knowledge-focused Stopped earlyThis study looked for new markers in blood and joint fluid to help doctors tell the difference between septic arthritis (a joint infection) and juvenile idiopathic arthritis (an inflammatory condition) in children. Researchers planned to analyze samples from 100 children under 15…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New lung camera could replace needle biopsies
Knowledge-focused Stopped earlyThis study aimed to see if a tiny camera on a thin tube (bronchoscopy) could help doctors diagnose diffuse lung diseases without needing a surgical lung biopsy. The camera takes live microscopic images of the air sacs. The study was stopped early, but it involved 38 adults with c…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Microscope inside the lungs reveals hidden damage in two diseases
Knowledge-focused Stopped earlyThis study used a special microscope on the tip of a thin tube (bronchoscope) to look at the smallest blood vessels in the lungs of people with scleroderma or emphysema. The goal was to see how these vessels change in each disease. Only 9 patients were enrolled before the study w…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Gut microbiome study in kids with autoimmune diseases ends early
Knowledge-focused Stopped earlyThis study aimed to compare the gut bacteria of children newly diagnosed with juvenile idiopathic arthritis, type 1 diabetes, or inflammatory bowel disease with those of their healthy siblings. Researchers wanted to see if differences in gut microbes and diet could explain why so…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Arthritis drugs and COVID: study probes immune response
Knowledge-focused Stopped earlyThis study looked at how immunosuppressive medications used for rheumatoid arthritis and spondyloarthritis affect the body's ability to fight COVID-19. Researchers measured viral load and immune responses in 150 patients and their infected family members. The goal was to understa…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Lupus and COVID vaccines: immune response under the microscope
Knowledge-focused Stopped earlyThis study aimed to understand how the COVID-19 vaccine impacts the immune system in people with lupus, a chronic autoimmune disease. Researchers planned to enroll lupus patients to measure their immune response to the vaccine and see if lupus disease activity or treatments affec…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
New hip implant put to the test: will it stay put?
Knowledge-focused Stopped earlyThis study looked at a specific hip implant shell (the Pinnacle Acetabular Shell) used in total hip replacement. Researchers wanted to see how much the implant moved (migrated) over two years using a special X-ray technique called RSA. They also tracked how patients felt and func…
Sponsor: DePuy Orthopaedics • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Elderly arthritis study reveals hidden health risks
Knowledge-focused Stopped earlyThis study aimed to understand how age influences serious health issues like infections, cancer, heart disease, and bone fractures in people with rheumatoid arthritis. Researchers compared patients over 65 with younger adults (18-50) who had the same disease. The study was stoppe…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Lab study explores how JAK inhibitors affect immune cells in arthritis
Knowledge-focused Stopped earlyThis study looked at how JAK-STAT inhibitors, a type of drug used for rheumatoid arthritis, affect certain immune cells called regulatory B cells. Researchers analyzed blood samples from 27 patients to see if these drugs could boost anti-inflammatory functions. The study was term…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Scientists probe immune cells in arthritic joints for clues
Knowledge-focused Stopped earlyThis pilot study analyzed special immune cells called regulatory T cells (Tregs) in the joint fluid of 19 people with rheumatoid arthritis during a flare-up. Researchers compared these cells to Tregs in the blood to understand how they behave in inflamed joints. No treatment was …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Tiny study probes hidden cause of foot pain in arthritis
Knowledge-focused Stopped earlyThis study looked at whether a condition called intermetatarsal bursitis (inflammation between foot bones) causes pain in people with rheumatoid arthritis. Researchers used MRI and ultrasound to examine the feet of 3 participants and tested steroid injections. The study was termi…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Study on arthritis and diabetes link halted early
Knowledge-focused Stopped earlyThis study looked at whether people with both rheumatoid arthritis and type 2 diabetes have a harder time controlling their diabetes than those with osteoarthritis and diabetes. Researchers planned to follow 176 adults to see how quickly they needed new diabetes treatments. Howev…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:07 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused Stopped earlyThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC
-
Tiny study on drug monitoring in scleroderma ends early
Knowledge-focused Stopped earlyThis study aimed to see if measuring the amount of mycophenolic acid in the blood could help doctors adjust the dose of mycophenolate mofetil (MMF) to better treat skin and lung problems in people with systemic sclerosis. Only 2 patients were enrolled before the study was termina…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:32 UTC